Other languages MEI Pharma, Inc. London S.E.

Equities

0JW9

US55279B3015

Market Closed - London S.E. Other stock markets 09:35:44 2023-03-01 am EST			5-day change	1st Jan Change
4.336 ^USD	-91.91%		+53.49%	-25.50%

May. 09	MEI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
Apr. 11	MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MEI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	May. 09
MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	Apr. 11
MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	Apr. 11
MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia	Mar. 26
MEI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 13
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023	Dec. 11
MEI Pharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 09
MEI Pharma, Inc. Declares Special Cash Dividend of Common Stock, Payable on December 6, 2023	Nov. 06
MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023	Nov. 02
MEI Pharma, Inc. Announces Board Changes	Nov. 01
MEI Pharma Solicits Proxies from Shareholders	23-10-18
Anson Funds hires Legion Partners' Gupta to build out activism strategy	23-10-03
MEI Pharma Issues Statement Regarding Anson Advisors and Cable Car?s Actions	23-09-28
MEI Pharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-26
MEI Pharma Reports Institutional Purchase of 32,040 Shares Along With 6,000 Put Options	23-09-26
MEI Pharma, Inc. Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab in Patients with Previously Treated Metastatic Colorectal Cancer	23-08-16
MEI Pharma, Inc. cancelled the acquisition of Infinity Pharmaceuticals, Inc. from The Vanguard Group, Inc. and others.	23-07-22
Anson Funds and Cable Car Capital Respond to MEI Pharma	23-07-19
MEI Pharma Responds to Anson and Cable Car Solicitation	23-07-18
Infinity Pharmaceuticals Shareholders Approve MEI Pharma Merger Deal	23-07-14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages MEI Pharma, Inc. London S.E.

Equities

0JW9

US55279B3015

Other languages

Filters